New biomarker aims at affordable bowel cancer test
20 May, 2012 by Tim DeanAustralian researchers have identified genes that can be used to detect the presence of bowel cancer, raising hopes of a new cost-effective blood test.
REVA Medical stent trial shows positive results
18 May, 2012 by Dylan Bushell-EmblingPatients enrolled in a pilot trial of REVA Medical's (ASX:RVA) ReZolve coronary stent have so far suffered no major adverse coronary events.
ResMed hunting for new CEO
18 May, 2012 by Dylan Bushell-EmblingResMed (ASX:RMD) is hunting internally and externally for a new CEO to replace founter Dr Peter Farrell when he steps down as CEO at the end of 2013.
AusBiotech web app for events makes its debut
17 May, 2012 by AusBiotechAs a further foray into social media and communication technologies, AusBiotech this week launched a web app at the AusMedtech 2012 conference that gave delegates access to all the event information in an easy and fun web format.
Biosceptre, University of Queensland to collaborate on cancer antibodies
16 May, 2012 by Dylan Bushell-EmblingBiosceptre and the University of Queensland’s AIBN research institute have teamed up to develop a production method for monoclonal antibodies designed to trigger cancer cell death.
Australian Synchrotron to use Bluechiip tracking tech
16 May, 2012 by Dylan Bushell-EmblingThe Australian Synchrotron will use a new tracking technology developed by Bluechiip (ASX:BCT) to keep track of samples in extreme temperatures.
Gene patents challenged again
16 May, 2012 by Tim DeanGene patents have hit the headlines once again with a Labor backbencher introducing a private member’s bill to ban patents on genetic material.
Medtech experts gather at AusMedtech annual conference
15 May, 2012 by AusBiotechAustralia’s largest medical technology conference, AusMedtech, has again attracted 300 delegates to its highly-specialised annual conference for medical devices and diagnostics experts.
Bioniche burn rate rises on animal health spend
14 May, 2012 by Dylan Bushell-EmblingBioniche (ASX:BNC) revealed its burn rate increased in the March quarter as it stepped up efforts to improve its bottom line through increased animal health sales.
Alchemia gaining US share for anticoagulant
14 May, 2012 by Dylan Bushell-EmblingUS sales of generic fondaparinux, the anticoagulant produced by Alchemia (ASX:ACL), are expected to have grown 120% year-on-year.
IPO-bound Ventus Medical eyes market growth
11 May, 2012 by Dylan Bushell-EmblingVentus Medical plans to use the proceeds of its upcoming ASX IPO to fund efforts to build a market for its sleep disorder breathing products.
Phosphagenics lands retail deal with David Jones
11 May, 2012 by Dylan Bushell-EmblingRetail chain David Jones has agreed to stock the Elixia range of skincare products from Melbourne-based Phosphagenics (ASX:POH).
AusBiotech investment mission to sign MOU with HKBIO
10 May, 2012 by AusBiotechAn AusBiotech investment mission to Hong Kong later this month will culminate in the signing of a memorandum of understanding (MOU) between AusBiotech and the Hong Kong Biotechnology Organization (HKBIO) to boost biotechnology development.
CathRx looks to delist from ASX
10 May, 2012 by Dylan Bushell-EmblingCardiac catheter company CathRx (ASX:CXD) will likely seek shareholder approval to go private after it raises funds to pursue a potential sale of the company.
BioDiem, VIVALIS team for viral vector research
09 May, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) and France's VIVALIS are exploring the feasibility of using BioDiem's LAIV flu virus to create a viral vector for non-influenza vaccines.
